Antibe Therapeutics Stock Short Ratio
| ATBPF Stock | USD 0.22 0.00 0.00% |
Antibe Therapeutics fundamentals help investors to digest information that contributes to Antibe Therapeutics' financial success or failures. It also enables traders to predict the movement of Antibe Pink Sheet. The fundamental analysis module provides a way to measure Antibe Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Antibe Therapeutics pink sheet.
Antibe |
Antibe Therapeutics Company Short Ratio Analysis
Antibe Therapeutics' Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.
| Competition |
Based on the latest financial disclosure, Antibe Therapeutics has a Short Ratio of 0.0 times. This is 100.0% lower than that of the Pharmaceuticals sector and 100.0% lower than that of the Health Care industry. The short ratio for all United States stocks is 100.0% higher than that of the company.
Antibe Short Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Antibe Therapeutics' direct or indirect competition against its Short Ratio to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Antibe Therapeutics could also be used in its relative valuation, which is a method of valuing Antibe Therapeutics by comparing valuation metrics of similar companies.Antibe Therapeutics is currently under evaluation in short ratio category among its peers.
Antibe Fundamentals
| Return On Equity | -0.4 | |||
| Return On Asset | -0.16 | |||
| Current Valuation | (19.98 M) | |||
| Shares Outstanding | 52.14 M | |||
| Shares Owned By Insiders | 7.79 % | |||
| Price To Earning | (1.67) X | |||
| Price To Book | 0.61 X | |||
| Price To Sales | 2.96 X | |||
| Gross Profit | 3.55 M | |||
| EBITDA | (25.14 M) | |||
| Net Income | (25.06 M) | |||
| Cash And Equivalents | 50.19 M | |||
| Cash Per Share | 0.96 X | |||
| Total Debt | 205 K | |||
| Debt To Equity | 0 % | |||
| Current Ratio | 14.65 X | |||
| Book Value Per Share | 0.90 X | |||
| Cash Flow From Operations | (16.92 M) | |||
| Earnings Per Share | (0.41) X | |||
| Target Price | 4.53 | |||
| Number Of Employees | 37 | |||
| Beta | 0.0997 | |||
| Market Capitalization | 22.59 M | |||
| Total Asset | 89.16 M | |||
| Retained Earnings | (12.08 M) | |||
| Working Capital | 1.45 M | |||
| Current Asset | 3.96 M | |||
| Current Liabilities | 2.51 M | |||
| Z Score | 66.0 | |||
| Net Asset | 89.16 M |
About Antibe Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Antibe Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Antibe Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Antibe Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Antibe Pink Sheet
Antibe Therapeutics financial ratios help investors to determine whether Antibe Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Antibe with respect to the benefits of owning Antibe Therapeutics security.